Skip to main content

Advertisement

Table 3 Serious adverse events in the safety population

From: Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

Serious adverse events Safety population (n = 80)
Patient with ≥1 serious adverse event 14 (17.5)
Pneumonia 7 (8.8)
Lung infection 2 (2.5)
Cerebral infarction 2 (2.5)
Bronchitis 1 (1.3)
Bronchopneumonia 1 (1.3)
Lobar pneumonia 1 (1.3)
Cerebral ischemia 1 (1.3)
Neutropenia 1 (1.3)
Cardiac failure 1 (1.3)
Cataract 1 (1.3)
Spinal compression fracture 1 (1.3)
Electrolyte imbalance 1 (1.3)
Multiple myelomaa 1 (1.3)
Deep vein thrombosis 1 (1.3)
  1. All values n (%)
  2. aMultiple myeloma was considered an adverse event when the disease worsened, but did not meet the study criteria for progressive disease